Market Signal Briefing

Joerg Hiller
Oct 02, 2025 02:01

Gala Games introduces 'Haunt and Haul' for Halloween, connecting games like Town Star, Vexi Villages, and Mirandus with unique events and rewards.

This October, Gala Games is launching an interconnected Halloween celebration, 'Haunt and Haul,' featuring a series of events across its gaming ecosystem. The festivities will span multiple games, including Town Star, Vexi Villages, Mirandus, Champions Arena, and Eternal Paradox, offering players a unique experience with rewards that carry over between games.

A Haunted Journey Across Worlds
Gala Games is orchestrating a multi-game event for the first time, allowing players to use their achievements in one game to gain advantages in another. The event kicks off with Town Star from October 14 to 17, where players can win the rare VEXI Scaremel NFT, enhancing their Candy Cart in Vexi Villages.

Following this, from October 23 to 27, Vexi Villages will offer the Link of the Brittle NFT, a special item for Mirandus players. The event continues with Mirandus from October 30 to November 3, where players can secure a Zombie Chemical Engineer Skin, which boosts performance in Town Star.

The event concludes with a final showdown in Town Star from November 4 to 7, where participants can compete for glory and $GALA tokens. All participants will receive the exclusive 'Haunted Circle Member' Discord role as a badge of honor.

The Great Halloween NFT Exchange
Each NFT obtained during the event is not just a collectible but a strategic asset for future gameplay. The Scaremel NFT enhances the Candy Cart in Vexi Villages, while the Link of the Brittle NFT and the Zombie Chemical Engineer Skin are designed to boost players' strategies across the games, making the event a gateway to future success in the Gala Games universe.

Champions Arena Joins the Celebration
Champions Arena is also participating with its Halloween-themed events, including a limited-time Halloween Avatar Skin Wardrobe available from October 22 to November 5. Players can also enjoy Hot Time Events from October 24 to 31, offering boosted rewards and reduced upgrade costs. A new Equipment Refine feature allows players to customize their gear further.

Eternal Paradox: Halloween Frenzy
Eternal Paradox will host a 72-hour Halloween showdown from October 31 to November 3. Players can engage in Arena PvP battles, aiming to climb the leaderboard by earning Event Points. Enhancements such as the Event Pass, Obscure Keep Fortress Skin, and Dark-affinity Featured Mercenaries will provide strategic advantages.

As the 'Haunt and Haul' event unfolds, Gala Games invites players to embrace the Halloween spirit by exploring new strategies, unlocking exclusive rewards, and participating in community challenges. For more details, visit the Gala Games news page.

Image source: Shutterstock

gala games
halloween
nft
gaming

Alvin Lang
Oct 02, 2025 02:26

Sui, SUIG, and Ethena collaborate to introduce suiUSDe, a Sui-native synthetic dollar, enhancing the DeFi ecosystem with innovative stablecoin solutions.

The Sui Foundation, in partnership with SUIG Holdings and Ethena, has announced the forthcoming launch of suiUSDe, a new Sui-native synthetic dollar token. This innovative asset aims to bolster Sui's DeFi ecosystem, marking a significant collaboration between a digital asset treasury company, a foundation, and a stablecoin provider, according to Sui Foundation.

Powering the Next Generation of Stable Assets
The suiUSDe token will be supported by a mix of digital assets and short futures positions, providing a stable and income-generating asset on the Sui network. This development positions Sui as the first non-EVM network to host such a stable asset, with backing from Ethena’s infrastructure. The revenue generated from the reserves will be used by both the Sui Foundation and SUIG to acquire additional SUI tokens, enhancing the ecosystem's value.

Adeniyi Abiodun, Co-Founder and Chief Product Officer of Mysten Labs, highlighted the significance of this launch as a new pillar in the Sui DeFi infrastructure, connecting stable assets directly to existing Sui infrastructure like decentralized exchanges. This initiative is expected to attract major financial institutions to the Sui ecosystem.

A Mechanism for Ecosystem Growth
The introduction of suiUSDe is set to drive ecosystem growth by channeling net income back into purchasing the native SUI token. This strategy aligns with the global trend of rising stablecoin transfer volumes, which have recently surpassed those of Visa and MasterCard combined, illustrating the market’s rapid expansion.

Sui's high-speed and scalable blockchain provides a robust foundation for stablecoin transactions, with a record $229 billion in stablecoin transfer volume recorded in August 2025, reinforcing its position as a premier platform for stablecoin movement.

Building the Future of Finance
Marius Barnett, Chairman of SUI Group, emphasized the strategic importance of suiUSDe as part of their vision to create a 'SUI Bank,' enhancing liquidity and value within the Sui ecosystem. Guy Young, CEO of Ethena Labs, noted Sui’s performance and composability as key factors in choosing it for launching this new stablecoin product beyond the EVM environment.

The suiUSDe launch further solidifies Ethena’s status as a leading digital dollar issuer, with the token forming part of Ethena’s Whitelabel product line, enabling high-performance chains and consumer-facing apps to launch their digital dollars. The suiUSDe is set to be available later this year, promising to enhance the DeFi landscape with cutting-edge stablecoin solutions.

Image source: Shutterstock

sui
suig
ethena
stablecoin

London prosecutors have secured a guilty plea in what is now being called the largest Bitcoin fraud case in history. Zhimin Qian, also known by the alias Zhang Yadi, admitted at Southwark Crown Court to orchestrating a massive cryptocurrency scam that defrauded over 128,000 investors.

Bitcoin blasted through $116,000 with a 3% daily gain even as the U.S. government officially entered shutdown, its first since 2018. The political stalemate over health-care funding has 750,000 federal workers on furlough and could cost about $400 million per day, yet risk assets shook off early nerves.

Despite delays, experts say the approval of several altcoin ETFs, including Solana's, are “really 100% now.”

Defiance ETFs has introduced an innovative exchange-traded fund (ETF) that combines exposure to some of the world's most valuable companies with Bitcoin. The fund, called the Defiance Trillion Dollar Club Index ETF (TRIL), debuted on Tuesday and aims to give investors access to a mix of top-tier tech companies and digital assets with a market capitalization exceeding $1 trillion.

Interim IRS guidance lifts Strategy's outlook by removing expected 15% tax exposure on unrealized bitcoin gains, strengthening earnings potential and reinforcing momentum from its massive cryptocurrency holdings. New IRS Guidance Frees Strategy From 15% Burden on Unrealized Bitcoin Gains Tax policy adjustments are reshaping corporate earnings expectations for firms with large cryptocurrency reserves. Strategy Inc.

TLDR

Sweden is considering establishing a national Bitcoin reserve to enhance its financial strategy and diversify state assets.
The proposal highlights Bitcoin’s potential as a hedge against inflation and a complementary asset to gold and foreign exchange reserves.
Lawmakers argue that Bitcoin’s global liquidity and capped supply make it an attractive addition to Sweden’s financial reserves.
The motion calls for the government to ensure that Bitcoin’s legal status remains unchanged and unaffected by future policy shifts.
Sweden’s growing interest in Bitcoin aligns with a broader trend of countries accumulating Bitcoin as a strategic financial asset.

Sweden could soon establish a national Bitcoin reserve, positioning itself as a key player in the global financial landscape. On October 1, a parliamentary motion titled “A Swedish Bitcoin Strategy” was introduced by Dennis Dioukarev and David Perez of the Sweden Democrats. The motion calls on the government to explore the creation of a Bitcoin reserve to complement existing financial assets like gold and foreign exchange reserves.

Proposal for National Bitcoin Reserve
The proposed Bitcoin reserve would aim to diversify Sweden’s financial holdings, as it faces growing geopolitical uncertainty. According to the lawmakers, Bitcoin could serve as a hedge against inflation and provide liquidity during crises.

“We believe that Bitcoin is an asset that can offer financial security and stability,” Dioukarev said in a statement.

The motion outlines the potential benefits of adding Bitcoin to Sweden’s reserves. These include diversification, as Bitcoin’s value is independent of any single country’s monetary policy. The lawmakers argue that the cryptocurrency’s capped supply and global liquidity make it an attractive addition to state-held assets.

Additionally, the proposal emphasizes the growing importance of digital innovation. Bitcoin’s rise has led some countries, including the United States, to establish national reserves. Sweden, the motion argues, should also capitalize on this trend to remain competitive on the global stage.

Political Context and Strategic Rationale
The Swedish motion follows a broader trend of countries accumulating Bitcoin as a strategic asset. In the United States, lawmakers recently advanced the GENIUS Act, which supports the creation of a national Bitcoin reserve. Similarly, the UK and Finland have accumulated Bitcoin through legal seizures, and other nations like the Czech Republic are exploring similar options.

Sweden’s proposal comes amid rising calls for financial sovereignty. Lawmakers argue that Bitcoin could safeguard Sweden’s financial autonomy in an increasingly uncertain global landscape.

“In the face of global financial instability, Bitcoin offers an alternative that is not tied to traditional monetary policies,” said Perez.

The Swedish motion also seeks to ensure that Bitcoin’s legal status remains intact. The proposal requests that the government confirm it will not alter the legal definition of tender or introduce a central bank digital currency. This will ensure that Bitcoin’s role as a reserve asset remains unaffected by future legislative changes.

Sweden’s stance toward cryptocurrency has been cautious in recent years, with regulators tightening rules on exchanges and miners. However, recent developments suggest that the country is becoming more open to digital assets. Several Swedish companies, including H100 Group AB and Refine Group AB, have recently added Bitcoin to their balance sheets as a treasury asset.

The motion suggests a budget-neutral approach for acquiring Bitcoin reserves. Law enforcement agencies would transfer seized Bitcoin to the Riksbank or another designated authority, rather than auctioning it off. This could help Sweden build a Bitcoin reserve without additional state spending, as the assets are already in government possession.

Bitcoin is now back trading above $115,000, but the recovery comes with a shadow that cannot be ignored. A new gap opened on the CME Bitcoin futures chart, and while the spot market has pushed higher since then, the presence of this gap opens up a bearish scenario. These gaps have a history of pulling Bitcoin back down to fill them, and the most recent one opens up questions about how long the current bullish momentum can last.

Bitcoin Opens Up Huge CME Gap
Crypto analyst Daan Crypto noted on the social media platform X how Bitcoin opened the week with a huge CME gap that has continued higher since the futures open. This gap is important, as it has been a while since Bitcoin opened with such a huge gap.

As shown in the chart image below, this CME gap is between $110,000 and $111,300. Gaps on CME futures have a tendency to close fairly quickly, meaning that Bitcoin often retraces to the level of the gap before resuming its trend. If that happens this time, the short-term structure of Bitcoin’s price action could deteriorate into a bearish momentum. 

Source: Chart from Daan Crypto Trades on X
However, Daan also noted that this gap should not be considered in play unless Bitcoin drops below $111,000. But if that happens, the futures chart could drag spot prices lower and turn recent strength into weakness.

What Does This Mean For Bitcoin?
A CME gap occurs because the Chicago Mercantile Exchange does not trade over the weekend, unlike the spot Bitcoin market, which operates 24/7. When Bitcoin makes a big move on Saturday or Sunday, CME futures reopen on Sunday evening at a different level than they closed on Friday, and this leaves an empty gap on the price chart. 

It’s common knowledge that Bitcoin tends to fill these gaps by returning to the level of the gap before continuing in its trend. If Bitcoin retraces to close this latest gap between the $110,000 to $111,000 range, it would erase the recovery that pushed it to $115,000 and bring the price back into a zone of uncertainty.

According to Daan Crypto, if that were to happen here, then the entire structure would look pretty bad in the short term. However, this might be one of those very few gaps that never closes or not until months later. This would most likely be the case, unless Bitcoin breaks below $111,000. A dip below $111,000 could ultimately see Bitcoin losing the $110,000 price level again. 

If Bitcoin can stay above $115,000 and there’s enough buying pressure, then the gap can be ignored in the short term. The next test will be whether buyers can sustain the recently found momentum and push towards $120,000.

At the time of writing, Bitcoin is trading at $116,380, up by 1.4% in the past 24 hours.

BTC trading at $116,300 on the 1D chart | Source: BTCUSDT on Tradingview.com
Featured image from Pixabay, chart from Tradingview.com

Ripple's leadership evolution is reinforcing long-term confidence as David Schwartz transitions from CTO to board member, ensuring XRP innovation, stability, and strategic continuity remain firmly in focus.

Institutional investors gain discounted access to AVAX and active treasury management as public debut targets enhanced token utility.

Key Takeaways

Avalanche Treasury Co. (AVAT) will merge with Mountain Lake to create a public vehicle for AVAX exposure.
AVAT offers institutional investors discounted access to AVAX and aims to accumulate over $1 billion in AVAX assets after going public.

Avalanche Treasury Co. (AVAT), a dedicated digital asset treasury company designed to strengthen the Avalanche ecosystem, is set to go public through a merger deal with Mountain Lake Acquisition Corp. (MLAC) valued at over $675 million, according to a Wednesday statement.

The transaction includes approximately $460 million in treasury assets post–private placement financing and aims to create a leading public vehicle for AVAX exposure. The combined company is expected to debut on Nasdaq in Q1 2026, pending approvals.

Operating in close partnership with the Avalanche Foundation, AVAT is launching with an initial AVAX token purchase at a discounted market price and will have an 18-month priority on Avalanche Foundation sales to US digital asset treasury companies.

The structure delivers exposure at a 0.77x NAV multiple, giving investors a 23% cheaper entry point than direct AVAX or ETF alternatives.

“Many institutions have difficulty accessing digital assets or are limited to holding native tokens without yield or ecosystem integration. We created Avalanche Treasury Co. to offer something we believe will be more valuable than passive exposure,” said AVAT CEO Bart Smith.

The company aims to accumulate more than $1 billion worth of AVAX after going public. Ava Labs founder Emin Gün Sirer will serve as strategic advisor, while Chief Business Officer John Nahas will join the public company’s board.

“We are very pleased to welcome AVAT to the Avalanche ecosystem,” said Emin Gün Sirer. “I’m honored to support them as an advisor. Their participation reflects the growing sophistication and momentum shaping Avalanche’s future.”

According to Paul Grinberg, Chairman & CEO of MLAC, the transaction reflects confidence in AVAT’s ability to execute at scale through an experienced team and advisory group.

“Avalanche’s architecture addresses real enterprise needs in ways other protocols simply don’t,” Grinberg stated. “What attracted us to this transaction is AVAT’s operational mandate and building a treasury that actively drives token utility and adoption, not just buying and holding.”

The transaction attracted investment from major institutions, including Dragonfly, ParaFi Capital, VanEck, FalconX, Galaxy Digital, Pantera Capital, CoinFund, IMC, Kraken, and others. FalconX will provide execution and credit services, while Monarq will serve as an asset manager for AVAT.

Disclaimer

South Korea’s SK Planet, part of SK Group, has announced plans to purchase MOCA Coin (MOCA) on the open market as it adopts Moca Network’s decentralized identity (DID) infrastructure. 

The initiative will introduce zero-knowledge proof technology and decentralized identity verification across SK Planet’s ecosystem, which serves 28 million users and 95,000 merchant partners.

Enterprise-scale decentralized identity
Moca Network, a project by Animoca Brands, is building a chain-agnostic identity layer designed to give users ownership of their data while ensuring interoperability across platforms. 

By integrating AIR Account and AIR Identity, SK Planet aims to allow merchants to verify user information with explicit consent, while ensuring that private data remains under user control.

“Partnering with Moca Network enables SK Planet to bring decentralized identity and privacy-preserving verification to our millions of customers and merchant partners,” said Kyosu Kim, chief business officer at SK Planet. “By leveraging AIR Kit and AIR Wallet, we can expand the benefits of OKI Club and reward our users with MOCA Coin while giving them greater control over their data. This is a strategic step forward in aligning with global standards for user privacy and digital identity.”

Kenneth Shek, project lead of Moca Network, added: 

“SK Planet’s purchase of MOCA Coin as well as its integration of AIR Kit infrastructure and adoption of zero-knowledge proofs mark an important milestone in returning data ownership to users at an enterprise scale.”

The partnership builds on the February 2025 launch of SK Planet’s OKI Club, which integrated AIR Wallet to let users earn and manage rewards. The company now plans to extend these capabilities with AIR Identity, enabling users to verify credentials and access rewards across multiple platforms, with features including token swaps and staking.

Featured image via Shutterstock. 

According to social posts and on-chain trackers, XRP appears poised for a sharp move that could leave little time for slow decisions. Trader Altcoin Gordon cautioned that XRP’s upcoming move might unfold quickly and with force, telling traders to be ready before it takes off.

Price has been stuck below $3 for weeks, and September produced no clear upward momentum, leaving traders on edge as regulators and markets add to uncertainty.

Trader Warning Spurs Urgency
Short-term charts show XRP compressing after a slide that began in July when the token crossed $3.60. Based on reports, Gordon’s shared chart points to prices tightening toward a breakout point.

Compression like this stores volatility. It does not promise an uptrend, but when a move comes it can be abrupt. Some traders see that as an opportunity; others see a risk of chasing a quick spike.

Mark my words, the next leg up for $XRP will be fast and aggressive.

You’re either positioned BEFORE it happens, or begin for an entry once it does.

Connect the dots or stay broke. pic.twitter.com/QCCFxyJe4P

— Gordon (@AltcoinGordon) September 29, 2025

Compression And Historical Runs
Reports have disclosed that research groups, including Sistine Research, say this is the third major compression since the last US election cycle.

Past compressions have been followed by big moves. In late 2024, XRP rose from $0.50 to above $3.40 within weeks — a rapid jump that surprised many.

Analysts now point to a range of possible outcomes, with targets that span from $8 to as much as $33 on extreme scenarios based on extensions and past cycle math. Those top-end figures are outliers and should be treated with caution.

XRPUSD now trading at $2.94. Chart: TradingView
On-Chain Flows
On-chain data from Santiment shows large wallets holding between 10 million and 100 million XRP added over $300 million in three days.

Those wallets now hold close to 8 billion XRP, levels last seen in August before earlier rallies. Such accumulation can be bullish, though it can also set up fast squeezes that benefit early sellers.

Momentum, ETFs And Market Sentiment
Meanwhile, market chatter has been shaped by hopes around potential XRP-based ETFs, with a key US decision expected in October. If approvals arrive, funds could flow in quickly.

If regulators delay or deny listings, sentiment could reverse. At the same time, broader crypto strength in Bitcoin and Ethereum has helped lift appetite for large-cap altcoins, and derivatives data shows rising futures volume and open interest around XRP.

XRP Price Action
XRP climbed to $2.94 today, up 3.30% as ETF hopes and technical setups drew attention. The $3.00 mark has become a near-term psychological target for some traders.

Whatever happens next, the market looks set for higher volatility. Investors will need both timing and discipline to navigate whichever direction the next move takes.

Featured image from Meta, chart from TradingView

Coinbase app integrating 1inch API to enhance token swapsDeFi
• October 1, 2025, 9:01PM EDT

Partner offers

The Block may may earn a commission if you use our partner offers, at no extra cost to you.

Quick Take
Coinbase app will integrate a 1inch swap API that will enhance non-custodial token swaps, the companies announced.
“The integration of the 1inch Swap API by Coinbase represents the DEX aggregator’s most significant U.S. client to date,” they said.
Coinbase's app will integrate a 1inch Swap API aimed at enhancing non-custodial token swaps, the companies said Wednesday.

"The integration of the 1inch Swap API by Coinbase represents the DEX aggregator’s most significant U.S. client to date," according to a statement.

Coinbase appears dedicated to growing decentralized exchange trading across its customer base. In August, the centralized exchange (CEX) said it was launching a DEX integration to give traders the ability to buy and sell "millions" of digital assets previously unavailable to users. The move came on the heels of Coinbase reporting a decline in spot trading volumes and revenue for the second quarter.

Teaming up with 1inch may help boost Coinbase's prospects as it seeks to grow its market footprint. 1inch is a DeFi ecosystem that has 25 million users and handles over $500 million in daily trades, according to the company.

"Together we’re enabling seamless access to DEXes within the Coinbase app," Coinbase's Head of Trading Scott Shapiro said.

In August, 1inch introduced native swaps between Solana and EVM networks, aiming to improve liquidity across ecosystems.

1inch co-founder Sergej Kunz said his company's "non-custodial swap products are the ideal solution for centralized players across both crypto and TradFi as they move to bring assets on-chain in a seamless and secure way."

Coinbase expanding into DeFi also folds into the exchange's plans to position itself as an "everything exchange" where users can trade tokenized stocks or bet on the outcomes of specific events via a prediction similar to Polymarket and Kalshi.

Disclaimer: The Block is an independent media outlet that delivers news, research, and data. As of November 2023, Foresight Ventures is a majority investor of The Block. Foresight Ventures invests in other companies in the crypto space. Crypto exchange Bitget is an anchor LP for Foresight Ventures. The Block continues to operate independently to deliver objective, impactful, and timely information about the crypto industry. Here are our current financial disclosures.

© 2025 The Block. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

AUTHOR RT Watson is a senior reporter at The Block who covers a wide array of topics including U.S.-based companies, blockchain gaming and NFTs. Formerly covered entertainment at The Wall Street Journal, where he wrote about Disney, Netflix, Warner Bros. and the creator economy while focusing primarily on technological disruption across media. Previous to that he covered corporate, economic and political news in Brazil while at Bloomberg. RT has interviewed a diverse cast of characters including CEOs, media moguls, top influencers, politicians, blue-collar workers, drug traffickers and convicted criminals. Holds a master's degree in Digital Sociology. See More

WHO WE ARE The Block is a news provider that strives to be the first and final word on digital assets news, research, and data. +
Follow us on Google News
More by RT Watson

Kinsale Capital Group, Inc. (KNSL - Free Report) closed the most recent trading day at $417.49, moving -1.83% from the previous trading session. This change lagged the S&P 500's daily gain of 0.34%. On the other hand, the Dow registered a gain of 0.09%, and the technology-centric Nasdaq increased by 0.42%.

Coming into today, shares of the company had lost 6.6% in the past month. In that same time, the Finance sector gained 1.52%, while the S&P 500 gained 3.54%.

Analysts and investors alike will be keeping a close eye on the performance of Kinsale Capital Group, Inc. in its upcoming earnings disclosure. The company's upcoming EPS is projected at $4.66, signifying a 10.95% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $449.2 million, indicating a 7.45% increase compared to the same quarter of the previous year.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $18.32 per share and a revenue of $1.8 billion, indicating changes of +14.07% and +13.42%, respectively, from the former year.

It is also important to note the recent changes to analyst estimates for Kinsale Capital Group, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Kinsale Capital Group, Inc. is currently sporting a Zacks Rank of #2 (Buy).

In terms of valuation, Kinsale Capital Group, Inc. is presently being traded at a Forward P/E ratio of 23.22. This expresses a premium compared to the average Forward P/E of 11.76 of its industry.

It's also important to note that KNSL currently trades at a PEG ratio of 1.56. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Insurance - Property and Casualty industry held an average PEG ratio of 2.57.

The Insurance - Property and Casualty industry is part of the Finance sector. This group has a Zacks Industry Rank of 30, putting it in the top 13% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Ero Copper Corp. (ERO - Free Report) closed the most recent trading day at $20.65, moving +2.08% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.34%. At the same time, the Dow added 0.09%, and the tech-heavy Nasdaq gained 0.42%.

Shares of the company witnessed a gain of 36.6% over the previous month, beating the performance of the Basic Materials sector with its gain of 4.75%, and the S&P 500's gain of 3.54%.

The upcoming earnings release of Ero Copper Corp. will be of great interest to investors. It is anticipated that the company will report an EPS of $0.57, marking a 111.11% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $215.45 million, indicating a 72.64% growth compared to the corresponding quarter of the prior year.

For the full year, the Zacks Consensus Estimates are projecting earnings of $2 per share and revenue of $777.53 million, which would represent changes of +156.41% and +65.36%, respectively, from the prior year.

Any recent changes to analyst estimates for Ero Copper Corp. should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.87% higher. Ero Copper Corp. presently features a Zacks Rank of #1 (Strong Buy).

Looking at valuation, Ero Copper Corp. is presently trading at a Forward P/E ratio of 10.12. For comparison, its industry has an average Forward P/E of 25.41, which means Ero Copper Corp. is trading at a discount to the group.

The Mining - Non Ferrous industry is part of the Basic Materials sector. Currently, this industry holds a Zacks Industry Rank of 50, positioning it in the top 21% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Ouster, Inc. (OUST - Free Report) ended the recent trading session at $27.41, demonstrating a +1.33% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.34% for the day. Meanwhile, the Dow gained 0.09%, and the Nasdaq, a tech-heavy index, added 0.42%.

Heading into today, shares of the company had lost 3.22% over the past month, lagging the Computer and Technology sector's gain of 8.07% and the S&P 500's gain of 3.54%.

The upcoming earnings release of Ouster, Inc. will be of great interest to investors. The company is expected to report EPS of -$0.43, up 20.37% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $36.75 million, up 30.88% from the year-ago period.

Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$1.58 per share and revenue of $144.25 million. These totals would mark changes of +24.04% and +29.84%, respectively, from last year.

Investors might also notice recent changes to analyst estimates for Ouster, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Ouster, Inc. presently features a Zacks Rank of #2 (Buy).

The Electronics - Miscellaneous Components industry is part of the Computer and Technology sector. This group has a Zacks Industry Rank of 31, putting it in the top 13% of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

In the latest trading session, Humacyte, Inc. (HUMA - Free Report) closed at $1.76, marking a +1.15% move from the previous day. This change outpaced the S&P 500's 0.34% gain on the day. Meanwhile, the Dow gained 0.09%, and the Nasdaq, a tech-heavy index, added 0.42%.

The company's stock has climbed by 15.23% in the past month, exceeding the Medical sector's gain of 1.97% and the S&P 500's gain of 3.54%.

Investors will be eagerly watching for the performance of Humacyte, Inc. in its upcoming earnings disclosure. The company is forecasted to report an EPS of -$0.17, showcasing a 48.48% upward movement from the corresponding quarter of the prior year.

Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.35 per share and revenue of $3.51 million. These totals would mark changes of +66.67% and 0%, respectively, from last year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Humacyte, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Humacyte, Inc. is holding a Zacks Rank of #4 (Sell) right now.

The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 80, positioning it in the top 33% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

October 01, 2025 19:20 ET

 | Source:

GBank Financial Holdings Inc.

LAS VEGAS, Oct. 01, 2025 (GLOBE NEWSWIRE) -- GBank Financial Holdings Inc. (the "Company"), the parent company of GBank, is pleased to share the press release of its strategic partner, BoltBetz. BoltBetz announced today that legendary world champion and global icon Mike Tyson has joined the company as both a strategic investor and promotional partner.

The full press release from BoltBetz can be found here:

Mike Tyson Joins BoltBetz as Strategic Investor and Promotional Partner to Usher in a New Era of Cashless Gaming

About GBank Financial Holdings Inc.

GBank Financial Holdings Inc. is a bank holding company headquartered in Las Vegas, Nevada and is listed on the Nasdaq Capital Market under the symbol “GBFH.” Our national payment and Gaming FinTech business lines serve gaming clients across the U.S. and feature the GBank Visa Signature® Card—a tailored product for the gaming and sports entertainment markets. The Bank is also a top national SBA lender, now operating across 40 states. Through our wholly owned bank subsidiary, GBank, we operate two full-service commercial branches in Las Vegas, Nevada to provide a broad range of business, commercial and retail banking products and services to small businesses, middle-market enterprises, public entities and affluent individuals in Nevada, California, Utah, and Arizona. Please visit www.gbankfinancialholdings.com for more information.

Available Information

The Company routinely posts important information for investors on its web site (under www.gbankfinancialholdings.com and, more specifically, under the News & Media tab at www.gbankfinancialholdings.com/press-releases). The Company intends to use its web site as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD (Fair Disclosure) promulgated by the U.S. Securities and Exchange Commission (the “SEC”). Accordingly, investors should monitor the Company’s web site, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations and webcasts.

The information contained on, or that may be accessed through, the Company’s web site is not incorporated by reference into, and is not a part of, this document.

For Further Information, Contact:

GBank Financial Holdings Inc.
Edward Nigro
Executive Chairman
702-851-4200
[email protected]

Source: GBank Financial Holdings Inc.

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Quantum Corporation (NASDAQ: QMCO) between November 15, 2024 and August 18, 2025, inclusive (the “Class Period”), of the important November 3, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased Quantum Corporation securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Quantum Corporation class action, go to https://rosenlegal.com/submit-form/?case_id=43932 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 3, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Quantum Corporation improperly recognized revenue during the fiscal year ended March 31, 2025; (2) as a result, Quantum Corporation would need to restate its previously filed financial statements for the fiscal third quarter ended December 31, 2024; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Quantum Corporation class action, go to https://rosenlegal.com/submit-form/?case_id=43932 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

Datavault AI Today

$1.36 +0.27 (+24.77%)

As of 04:00 PM Eastern

52-Week Range$0.25▼

$2.68Price Target$7.00

A quiet corner of the tech market has suddenly become the center of attention. Shares of Datavault AI NASDAQ: DVLT, an artificial intelligence (AI) and data monetization company, have skyrocketed over 300% in the last 30 days, placing the stock on trending lists and capturing the interest of growth-focused investors.

For many, a surge of this magnitude raises a critical question: Is this a sustainable breakout or just a temporary, hype-driven rally? A closer look at the events driving this move reveals a rally built on a solid foundation. The company has recently secured a substantial capital infusion and a strategic technology partnership with a major industry player, signaling a significant shift in its operational and investment profile.

Get Datavault AI alerts:

A Nine-Figure Deal Fortifies the Balance Sheet
For any small-cap technology company, securing adequate funding is a primary challenge. In late September 2025, Datavault AI announced a strategic investment agreement with Scilex Holding Company NASDAQ: SCLX for $150 million. This deal effectively addresses one of the most significant risks for investors in this space: the constant threat of cash burn and the potential for future stock offerings that can dilute the value of existing shares.

The investment, notably executed in Bitcoin, is structured in two parts. An initial tranche of approximately $8 million has already closed, with the remainder subject to shareholder approval. This capital is to be used for operations and serves as growth fuel earmarked for specific, high-potential projects. To put this into perspective, Datavault AI reported revenue of $1.74 million in the second quarter of 2025. This nine-figure investment represents a monumental increase in the resources at its disposal. According to the company, the funds will be used to:

Build out a proprietary supercomputer infrastructure.
Expand its independent data exchanges, with a strategic focus on the valuable biotech sector.

For investors, this infusion provides a long operational runway, allowing Datavault AI to execute its ambitious growth plans from a position of financial strength rather than necessity.

A Blue-Chip Seal of Approval
Days after securing its financial future, Datavault AI announced a move that provided an endorsement of its core technology. The company announced a multi-million-dollar resource commitment from International Business Machines NYSE: IBM, a global leader in artificial intelligence. This partnership is a signal of deep validation from one of the most respected names in the tech industry, targeting a generative AI market that analysts project could add up to $4.4 trillion in annual economic value.

The commitment includes an estimated $5 million worth of professional services, providing Datavault AI with access to 20,000 hours of expertise from IBM's elite solution architects and AI engineers. This collaboration is designed to accelerate Datavault AI’s product roadmap by integrating its platform with IBM's respected watsonx.ai and watsonx.governance technologies. For a small company, this kind of third-party validation is invaluable. It suggests that after extensive due diligence, IBM sees significant potential in Datavault AI’s technology. This external seal of approval dramatically reduces the perceived technology risk for investors and elevates the company's credibility in a competitive market.

Immediate Execution: From News to Action
A key question for investors following major company announcements is "What's next?" Datavault AI provided a swift and tangible answer. On October 1, the company demonstrated its ability to immediately leverage its newfound momentum by signing a Memorandum of Understanding with Korea Aerospace University (KAU).

This strategic move leverages the company's patented VerifyU™ platform to enter the high-value aerospace sector. The partnership aims to pioneer digital credentialing for the industry, beginning with a pilot identity verification initiative in Korea. This development serves as immediate, tangible proof that the company's leadership is effectively converting its recent strategic wins into actionable business development. For investors, it is a key indicator of effective management, showing that the company is already unlocking new, global revenue opportunities.

Reassessing Valuation and What Lies Ahead
Datavault AI Stock Forecast Today12-Month Stock Price Forecast:
$7.00
414.71% Upside

Strong Buy
Based on 2 Analyst Ratings

Current Price$1.36High Forecast$11.00Average Forecast$7.00Low Forecast$3.00Datavault AI Stock Forecast Details

With these catalysts in place, Wall Street is taking notice. Analysts have assigned a consensus Strong Buy rating to the stock, with an average 12-month price target of $7.00. Set against a current market capitalization of approximately $233 million, this target implies substantial upside potential if the company executes its newly funded initiatives.

One notable metric is the stock's short interest, which stood at over 20% of the public float as of mid-September. While this indicates a portion of the market remains skeptical, it also introduces the potential for a short squeeze. If Datavault AI continues to deliver on its plans, traders who bet against the stock may be forced to buy shares to cover their positions, a dynamic that can amplify upward price movement.

Taken together, the recent events represent a fundamental inflection point. Datavault AI has successfully secured its financial future, gained a powerful technology endorsement from an industry leader, and demonstrated its ability to execute on its growth strategy. For investors, this combination of a fortified balance sheet, validated technology, and proven momentum has fundamentally improved the company's risk profile, making it a compelling name to watch in the evolving AI landscape.

Should You Invest $1,000 in Datavault AI Right Now?Before you consider Datavault AI, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Datavault AI wasn't on the list.

While Datavault AI currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Tortoise Capital today announced the following unaudited balance sheet information and asset coverage ratio updates for closed-end funds TYG and TEAF. OVERLAND PARK, KS / ACCESS Newswire / October 1, 2025 / Tortoise Energy Infrastructure Corp. (NYSE:TYG) today announced that as of September 30, 2025, the company's unaudited total assets were approximately $1.1 billion and its unaudited net asset value was $810.3 million, or $47.01 per share.

MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Shamis & Gentile, P.A, (“Shamis & Gentile”) issues this corrected notice to clarify the deadline to seek appointment as Lead Plaintiff in the securities class action lawsuit Shamis & Gentile filed against Charter Communications, Inc. (“Charter” or the “Company”) (Nasdaq:CHTR) and certain of its officers and/or directors (collectively, “Defendants”). The original notice issued on August 15, 2025 inadvertently stated that the deadline to seek appointment as Lead Plaintiff is October 13, 2025. The correct deadline to seek appointment as Lead Plaintiff is October 14, 2025.

The class action, captioned Sandoval v. Communications, Inc. et al., Case No. 1:25-cv-06747, filed in the United States District Court, Southern District of New York, is on behalf of all persons who purchased or otherwise acquired Charter common stock, purchased call options on Charter common stock, or sold put options on Charter common stock, between July 26, 2024 and July 24, 2025, inclusive (the “Class Period”), and were damaged thereby (the “Class”). The class action is brought under Sections 10(b) and 20(a) of the Securities Exchange Act, 15 U.S.C. Sections 78j(b) and 78t(a); and SEC Rule 10b-5 promulgated thereunder by the SEC, 17 C.F.R. Section 240.10b-5.

If you are an investor who purchased or otherwise acquired Charter common stock, and/or traded the relevant Charter options, during the Class Period, you have until October 14, 2025 to ask the Court to appoint you as Lead Plaintiff for the Class. For more information go to:

Charter Securities Fraud Class Action

Impacted investors may also contact attorney David Abel at [email protected] or (305) 479-2299. There is no cost or obligation to you.

Charter is a leading broadband connectivity company and cable operator. The Company operates in 41 states with services available to more than 57 million homes and businesses.

The class action complaint alleges Defendants failed to disclose material adverse facts about the Company’s business, operations, and outlook. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the impact of the Federal Communications Commission’s (“FCC”) Affordable Connectivity Program ("ACP") end was a material event the Company was unable to manage or promptly move beyond; (ii) the ACP end was having a sustaining impact on Internet customer declines and revenue; (iii) neither was the Company executing broader operations in a way that would compensate for, or overcome the impact, of the ACP ending; (iv) the Internet customer declines and broader failure of Charter’s execution strategy created much greater risks on business plans and earnings growth than reported; (v) accordingly, the Company had no reasonable basis to state the Company was successfully executing operations, managing causes of Internet customer declines, or provide overly optimistic statements about the long term trajectory of the Company and EBITDA growth; and (vi) as a result of the foregoing, Defendants materially misled with, and/or lacked a reasonable basis for, their positive statements about the Company’s business, operations, outlook during the Class Period.

On July 25, 2025, Charter issued a press release announcing second quarter 2025 financial results. The Company reported EBITDA of $5.7 billion, which suggested 0.5% growth year-over-year. However, analysts and investors quickly realized that the so-called growth was on account of a $45 million one-time benefit to “other revenue.” Had this event been excluded, EBITDA would have missed consensus estimates by 2.4% and shown a second quarter decline of 0.3% year-over-year.

At the same time, Charter reported total Internet customers decreased by 117,000 for the second quarter of 2025. The decline of Internet customers was nearly double from the 66,000 reported in the prior quarter. Internet customer declines had also increased year-over-year when compared to a loss of 99,000 customers reported in the second quarter of 2024.

These events caused Charter’s stock price to fall $70.25 per share, or 18.4%, to close at $309.75 per share on July 25, 2025.

If you suffered a loss in Charter stock or the relevant options, you have until October 14, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery does not require that you serve as a lead plaintiff.

About Shamis & Gentile P.A.

Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis Gentile has recovered over $1 billon for consumers nationwide. Its extensive experience, expertise, and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts, and mass arbitrations.

Contact

David Abel
Shamis & Gentile, P.A.
14 NE 1st Ave, Ste 705
Miami, FL 33132
[email protected]
Tel: (305) 479-2299
www.ShamisGentile.com

SANTA MONICA, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Beauty innovator Oliveda International, Inc. (OTCID: OLVI) and its Olive Tree People Inc. subsidiary will be rolling out the longest red carpet ever for ancient olive trees and 69,000 waterless beauty pioneers this weekend in downtown Los Angeles. The companies are creating a once-in-a-lifetime art installation in conjunction with the Million Dollar Theatre on South Broadway in downtown Los Angeles.

The fastest-growing waterless beauty company, Olive Tree People Inc., and the largest olive tree conservation organization are creating a once-in-a-lifetime art installation in downtown Los Angeles and are rolling out what is likely the longest red carpet in history for olive trees and its 69,000 waterless beauty pioneers.

With the kind permission of the City of Los Angeles, the entire stretch of South Broadway will be closed to allow for this very special event.

With this unique art installation featuring hundreds of ancient olive trees on South Broadway in downtown Los Angeles, Olive Tree People will give these magical trees a voice, even allowing their unique frequencies to be heard, creating a magical experience together with artist and two-time Grammy Award-winner, Colbie Caillat.

Founder and CEO Thomas Lommel, commented, "When we first made our olive trees and their frequencies available to everyone in 2015, I dreamed of holding such a concert in downtown LA.

“With this unique event at the Million Dollar Theatre, the oldest theater in Los Angeles and the world's only olive tree art installation, we want to honor the 7,000-year history of olive trees and celebrate our 69,000 waterless beauty pioneers who, in less than two years, have launched the waterless beauty movement in North America on its way to Europe and the rest of the world.

“Waterless beauty is much more than just the new clean beauty. It's where self-love begins and is, therefore, the fastest-growing sector in the entire global beauty industry with Olive Tree People as the pioneer and leading company. In recent months, under the umbrella of Olive Tree People, we have developed new, innovative, and truly unique products and brands, which we are presenting today to our 69,000 Waterless Beauty pioneers and will subsequently introduce to the rest of the world through our Waterless Beauty education program. All of these new products and brands are innovative and, therefore, unique worldwide, based on Waterless Beauty formulations and the unique active ingredient hydroxytyrosol.

“With these unique products and new brands, we expect to exceed our projected hypergrowth of 3000% in 2024 and 2025, and, I am convinced, multiply the value of our company many times over.  By early 2025, the company's value is projected to be well over one billion.”

About Oliveda International, Inc. 
Oliveda International, Inc. and its subsidiary, Olive Tree People Inc., as well as the European companies, Olive Tree People Europe AG and Oliveda Deutschland GmbH, as well as Olive Tree Farmers SL, were founded by the German real estate investor Thomas Lommel and have more than 20 years of experience in management and organic certification growing mountain olive trees, in the extraction of first-class, internationally award-winning extra virgin olive oils, the extraction of hydroxytyrosol, and in the production and distribution of cosmetic and holistic waterless products related to the olive tree. Lommel is the inventor of the Olive Tree Therapy 10 years in 14 days as well as the inventor of olive matcha, which is based on the ground olive leaf. Also unique is the coffee replacement developed by Lommel, which is based on olive leaf and hydroxytyrosol. In addition, Lommel is successfully active in the rapidly growing mindfulness industry with the olive tree sound bath meditation he developed and the frequencies of his olive trees, which he makes available worldwide.

In addition to the registered beauty brands, Oliveda and LA Dope, as well as OLIVE re:connected to Nature, The Intuition of Nature, and Olive Mush, to name just a few brands, Lommel is the region's largest conservationist and protector of over 30,000 one-hundred-year-old mountain olive trees, and, with his Thomas Lommel Foundation, he brings the water that he does not use into his waterless beauty products to the people of Africa by building water wells on site.

In addition to online sales and a Europe-wide branch network of thousands of retail stores, Oliveda Deutschland GmbH operates its own flagship stores in Berlin and Düsseldorf.

The brand's treatment concepts are unique worldwide, and their effectiveness has been confirmed by conventional medicine. Read our book The Olive Tree Therapy 10 Years in 14 Days. Waterless beauty has been called “The Next Big Thing” in articles in U.S. Vogue, Harper's Bazaar, InStyle, Elle, Madame, Forbes, and many other industry publications, as well as by Mintel, a world-leading futurology institute. Gigi Hadid and many other celebrities are already Oliveda fans and support its success.   Further information on Oliveda International, Inc. and its subsidiaries and associate companies and brands can be found at www.olivetreepeople.com

Forward-Looking Statements
This press release may contain statements, estimates or projections that constitute "forward-looking statements" pursuant to the safe harbor provisions of the U.S. federal securities laws. Generally, the words "believe," "expect," "intend," "estimate," "anticipate," "project," "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties, which may be found in the Company’s filings with OTC Markets Group Inc., that could cause actual results to differ materially from the Company's historical experience and present expectations or projections. Investors should not place undue reliance on forward-looking statements, which speak only as of the date they are made.  The Company expressly disclaims any obligation or intention to publicly update or revise any forward-looking statements unless otherwise required by law.

October 01, 2025 20:00 ET

 | Source:

HUTCHMED (China) Limited

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Congress 2025, taking place on October 17-21, 2025 in Berlin, Germany.

Results from the FRUSICA-2 registration study of the fruquintinib and sintilimab combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma will be presented in a Mini Oral session. Additionally, further analyses of the fruquintinib FRUSICA-1 study in endometrial cancer and the savolitinib SACHI and SAVANNAH studies in non-small cell lung cancer will be presented during the poster sessions.

Details of the presentations are as follows:

Abstract titlePresenter / Lead authorPresentation details
SPONSORED STUDIES  Fruquintinib (FRUQ) plus sintilimab (SIN) versus axitinib (AXI) or everolimus (EVE) monotherapy as 2L treatment in pts with locally advanced or metastatic renal cell carcinoma (RCC): results from phase 3 part of a randomized, open-label, active-controlled phase 2/3 study (FRUSICA-2)Zhenhua Liu
(Chengdu, China)2592MO
Mini Oral Session 1:
GU tumours, renal & urothelial
Friday, Oct 17, 2025
Karlsruhe Auditorium - Hall 5.2
16:00 - 17:30 CESTA Fruquintinib Expanded Access Program (EAP) to Provide Treatment for Patients With Metastatic Colorectal Cancer (mCRC)Stefan Kasper-Virchow 
(Essen, Germany)794P
Poster Session:
Colorectal cancerFruquintinib plus tislelizumab in microsatellite stable metastatic colorectal cancer: Results from a phase 1b/2 studyN. Arvind Dasari 
(Houston, USA)799P
Poster Session:
Colorectal cancerA novel artificial intelligence (AI) imaging biomarker of tumor vascularity and heterogeneity radiomics to predict survival benefit of fruquintinib vs placebo in metastatic colorectal cancer (mCRC)Sara Lonardi 
(Padua, Italy)804P
Poster Session:
Colorectal cancerSafety and tolerability of fruquintinib: Pooled analysis of three placebo-controlled studies in patients with metastatic colorectal cancerCathy Eng 
(Nashville, USA)811P
Poster Session:
Colorectal cancerAssociation between Metabolic Syndrome (MetS) and clinical outcomes of Fruquintinib plus Sintilimab in Previously Treated Advanced Endometrial Cancer (EMC) Patients with pMMR Status: results from FRUSICA-1 studyDanbo Wang
(Shenyang, China)1230eP
Poster Session:
Gynaecological CancerctDNA analysis in phase 3 SACHI trial: savolitinib (savo) plus osimertinib (osi) versus chemotherapy (chemo) in MET-amplified (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI)Yongfeng Yu 
(Shanghai, China)1954P 
Poster Session:
NSCLC, metastaticSAVANNAH: Safety and tolerability of osimertinib (osi) + savolitinib (savo) in EGFRm advanced NSCLC with MET overexpression and/or amplification (OverExp/Amp) following disease progression on osiQuincy Siu-chung Chu 
(Edmonton, Canada)1955P 
Poster Session:
NSCLC, metastaticMET testing and treatment (tx) sequencing after progression on first line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and acquired MET overexpression and/or amplification (OverExp/Amp): interim analysis of a global real world (rw) studyJulia Rotow
(Boston, USA)1956P 
Poster Session:
NSCLC, metastatic   INVESTIGATOR-INITIATED STUDIES  Fruquintinib plus sintilimab and SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated surgical and survival results from the single-arm, phase 2 clinical trialFei Ma
(Zhengzhou, China)2159P 
Poster Session:
Oesophagogastric cancerFruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, Phase II StudyWangjun Liao
(Guangzhou, China)898eP
E-poster Session:
Colorectal cancerThe efficacy and safety of surufatinib combined with chemotherapy in the first-line treatment of advanced periampullary carcinoma: a single arm, prospective, exploratory clinical studyQianqian Wang
(Nanjing, China)929P
Poster Session:
Developmental therapeuticsSurufatinib-Based Late-Line Therapy Outcomes in Recurrent Metastatic NSCLC: Monotherapy and Vinorelbine Combination RegimensYanfang Zheng
(Guangzhou, China)1884P
Poster Session:
NSCLC, metastaticSurufatinib combined with Toripalimab, Pemetrexed, and Platinum in Advanced Non-Squamous Non-Small Cell Lung Cancer (nsg-NSCLC): Final Phase II Results from a Single-Center TrialWenfeng Fang/ Li Zhang
(Guangzhou, China)1887P
Poster Session:
NSCLC, metastaticEfficacy/safety and preliminary scRNA-seq results of surufatinib plus gemcitabine and nab-paclitaxel as neoadjuvant therapy in resectable and borderline resectable pancreatic cancerSong Gao/ Jihui Hao
(Tianjin, China)2236P
Poster Session:
Pancreatic cancerEfficacy and Safety of Surufatinib in Patients with Advanced Soft Tissue Sarcoma After Failure of Anthracycline Chemotherapy and Prior Effective Antiangiogenic Therapy: A Single-Arm, Prospective, Exploratory Phase II StudyXiaowei Zhang/ Zhiguo Luo
(Shanghai, China)2716P
Poster Session:
Sarcoma    About Fruquintinib

Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE®. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA®.

About Savolitinib

Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS®.

About Surufatinib

Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA®. HUTCHMED currently retains all rights to surufatinib worldwide.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fruquintinib, surufatinib and savolitinib, the further clinical development for fruquintinib, surufatinib and savolitinib, its expectations as to whether any studies on fruquintinib, surufatinib and savolitinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib, surufatinib and savolitinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fruquintinib, surufatinib and savolitinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as sintilimab and toripalimab as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries+852 2121 8200 / [email protected]  Media Enquiries FTI Consulting –+44 20 3727 1030 / [email protected] Atwell / Alex Shaw+44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)Brunswick – Zhou Yi+852 9783 6894 (Mobile) / [email protected]  Panmure LiberumNominated Advisor and Joint BrokerAtholl Tweedie / Emma Earl / Rupert Dearden+44 20 7886 2500  CavendishJoint BrokerGeoff Nash / Nigel Birks+44 20 7220 0500  Deutsche NumisJoint BrokerFreddie Barnfield / Jeffrey Wong / Duncan Monteith+44 20 7260 1000